GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (BUE:NVS) » Definitions » E10

Novartis AG (BUE:NVS) E10 : ARS1,544.96 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Novartis AG E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Novartis AG's adjusted earnings per share data for the three months ended in Mar. 2024 was ARS2,207.350. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ARS1,544.96 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Novartis AG's average E10 Growth Rate was 5.70% per year. During the past 3 years, the average E10 Growth Rate was 8.70% per year. During the past 5 years, the average E10 Growth Rate was 5.20% per year. During the past 10 years, the average E10 Growth Rate was 1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Novartis AG was 8.70% per year. The lowest was -3.40% per year. And the median was 1.75% per year.

As of today (2024-04-28), Novartis AG's current stock price is ARS26495.50. Novartis AG's E10 for the quarter that ended in Mar. 2024 was ARS1,544.96. Novartis AG's Shiller PE Ratio of today is 17.15.

During the past 13 years, the highest Shiller PE Ratio of Novartis AG was 21.68. The lowest was 12.78. And the median was 16.91.


Novartis AG E10 Historical Data

The historical data trend for Novartis AG's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG E10 Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 162.32 169.39 270.41 462.43 1,472.33

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 561.20 720.69 1,137.75 1,472.33 1,544.96

Competitive Comparison of Novartis AG's E10

For the Drug Manufacturers - General subindustry, Novartis AG's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Shiller PE Ratio falls into.



Novartis AG E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2207.35/106.4611*106.4611
=2,207.350

Current CPI (Mar. 2024) = 106.4611.

Novartis AG Quarterly Data

per share eps CPI Adj_EPS
201406 16.737 101.517 17.552
201409 22.058 101.247 23.194
201412 10.432 100.704 11.028
201503 93.842 100.339 99.568
201506 13.630 100.464 14.444
201509 14.480 99.785 15.449
201512 11.390 99.386 12.201
201603 24.535 99.475 26.258
201606 20.970 100.088 22.305
201609 24.165 99.604 25.829
201612 12.682 99.380 13.586
201703 21.584 100.040 22.969
201706 27.370 100.285 29.056
201709 30.841 100.254 32.751
201712 32.080 100.213 34.080
201803 34.656 100.836 36.589
201806 165.103 101.435 173.284
201809 50.783 101.246 53.399
201812 38.459 100.906 40.576
201903 59.417 101.571 62.278
201906 260.032 102.044 271.288
201909 99.548 101.396 104.521
201912 58.578 101.063 61.707
202003 117.932 101.048 124.250
202006 110.905 100.743 117.200
202009 124.723 100.585 132.010
202012 149.739 100.241 159.031
202103 163.946 100.800 173.154
202106 242.509 101.352 254.733
202109 238.583 101.533 250.164
202112 1,462.335 101.776 1,529.659
202203 212.597 103.205 219.304
202206 185.308 104.783 188.276
202209 200.088 104.835 203.192
202212 228.004 104.666 231.914
202303 426.708 106.245 427.577
202306 532.800 106.576 532.228
202309 594.915 106.570 594.310
202312 2,931.320 106.461 2,931.320
202403 2,207.350 106.461 2,207.350

Add all the adjusted EPS together and divide 10 will get our e10.


Novartis AG  (BUE:NVS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Novartis AG's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=26495.50/1544.96
=17.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Novartis AG was 21.68. The lowest was 12.78. And the median was 16.91.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Novartis AG E10 Related Terms

Thank you for viewing the detailed overview of Novartis AG's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (BUE:NVS) Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.